PMID- 31719675
OWN - NLM
STAT- MEDLINE
DCOM- 20210618
LR  - 20210618
IS  - 1476-5454 (Electronic)
IS  - 0950-222X (Print)
IS  - 0950-222X (Linking)
VI  - 34
IP  - 8
DP  - 2020 Aug
TI  - Longitudinal neovascular changes on optical coherence tomography angiography in 
      proliferative diabetic retinopathy treated with panretinal photocoagulation alone 
      versus with intravitreal conbercept plus panretinal photocoagulation: a pilot 
      study.
PG  - 1413-1418
LID - 10.1038/s41433-019-0628-3 [doi]
AB  - PURPOSE: To investigate the longitudinal changes in neovascularization of the 
      retinal elsewhere (NVE) size on optical coherence tomography angiography (OCTA) 
      in proliferative diabetic retinopathy (PDR) treated by panretinal 
      photocoagulation (PRP) alone or by single intravitreal conbercept injection plus 
      PRP. METHODS: A prospective pilot study. Forty-four PDR eyes with NVE confirmed 
      by fundus fluorescein angiography (FFA) and OCTA were included. They were 
      assigned to receive PRP alone (PRP group) or intravitreal conbercept injection 
      plus PRP (combination group). Ophthalmic examinations, including BCVA and OCTA to 
      measure the NVE size, were performed at baseline before each PRP session, and at 
      1, 3, and 6 months. RESULTS: Twenty-nine eyes were included in the PRP group, and 
      15 eyes were included in the combination group. There was no significant 
      difference between the two groups with respect to age, BCVA, and NVE area at 
      baseline. In both groups, there was a significant (P < 0.05) NVE size reduction 
      during the majority of study visits, with the reduction observed in the 
      combination group significantly larger than that in the PRP group. No significant 
      BCVA changes were observed in either groups, except that in the PRP group, the 
      BCVA at 3 months was significantly improved (P < 0.05). No deaths or unexpected 
      adverse events (AEs) were reported. CONCLUSIONS: Intravitreal conbercept plus PRP 
      was more effective than PRP monotherapy in NVE regression. Precise quantification 
      of the NVE area by OCTA makes it a useful tool for monitoring the response of 
      retinal neovascular lesions to the therapy.
FAU - He, Feng
AU  - He F
AD  - Department of Ophthalmology, Peking Union Medical College Hospital, Key Lab of 
      Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China.
FAU - Yu, Weihong
AU  - Yu W
AD  - Department of Ophthalmology, Peking Union Medical College Hospital, Key Lab of 
      Ocular Fundus Diseases, Chinese Academy of Medical Sciences and Peking Union 
      Medical College, Beijing, China. yuweihongeye@foxmail.com.
LA  - eng
PT  - Journal Article
DEP - 20191112
PL  - England
TA  - Eye (Lond)
JT  - Eye (London, England)
JID - 8703986
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 1P05PW62F3 (KH902 fusion protein)
SB  - IM
MH  - Angiogenesis Inhibitors/therapeutic use
MH  - Combined Modality Therapy
MH  - *Diabetes Mellitus
MH  - *Diabetic Retinopathy/drug therapy/surgery
MH  - Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - Laser Coagulation
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Recombinant Fusion Proteins
MH  - Tomography, Optical Coherence
MH  - Visual Acuity
PMC - PMC7376016
COIS- The authors declare that they have no conflict of interest.
EDAT- 2019/11/14 06:00
MHDA- 2021/06/22 06:00
PMCR- 2019/11/12
CRDT- 2019/11/14 06:00
PHST- 2019/04/01 00:00 [received]
PHST- 2019/09/22 00:00 [accepted]
PHST- 2019/08/20 00:00 [revised]
PHST- 2019/11/14 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2019/11/14 06:00 [entrez]
PHST- 2019/11/12 00:00 [pmc-release]
AID - 10.1038/s41433-019-0628-3 [pii]
AID - 628 [pii]
AID - 10.1038/s41433-019-0628-3 [doi]
PST - ppublish
SO  - Eye (Lond). 2020 Aug;34(8):1413-1418. doi: 10.1038/s41433-019-0628-3. Epub 2019 
      Nov 12.